HRT Financial’s Metacrine, Inc. Common Stock MTCR Stock Holding History

HRT Financial’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-23,589	Closed	-$15K	–	4139
2021 Q4	$15K	Buy	+23,589	New	+$42.1K	﹤0.01%	2991

Other funds holding MTCR

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial's MTCR Position: Q1 2022 in Review

HRT Financial sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2022, closing a stake of 23,589 shares — an estimated $15K sold.

HRT Financial first reported a position in MTCR in Q4 2021 and held it in 1 quarter. The position peaked at $15K in Q4 2021. 31 funds tracked by Wall St. Rank hold MTCR as of Q1 2022.

HRT Financial reported no remaining Metacrine, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
HRT Financial sold 23,589 Metacrine, Inc. Common Stock shares in Q1 2022, an estimated $15K.
HRT Financial first reported a position in Metacrine, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
HRT Financial's Metacrine, Inc. Common Stock position peaked at $15K in Q4 2021.
31 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2022.

Based on HRT Financial's 13F filing for Q1 2022, filed 16 May 2022.